Citations (43)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Yue Zhao, Xiaoqiu Dong, Rongguo Li, Xiao Ma, Jian Song, Yingjie Li & Dongwei Zhang. (2015) Evaluation of the pathological response and prognosis following neoadjuvant chemotherapy in molecular subtypes of breast cancer. OncoTargets and Therapy 8, pages 1511-1521.
Read now
Read now
Articles from other publishers (42)
Sergiusz Łukasiewicz, Marcin Czeczelewski, Alicja Forma, Jacek Baj, Robert Sitarz & Andrzej Stanisławek. (2021) Breast Cancer—Epidemiology, Risk Factors, Classification, Prognostic Markers, and Current Treatment Strategies—An Updated Review. Cancers 13:17, pages 4287.
Crossref
Crossref
Mirco Pistelli, Filippo Merloni, Sonia Crocetti, Laura Scortichini, Laura Tassone, Luca Cantini, Veronica Agostinelli, Lucia Bastianelli, Agnese Savini & Rossana Berardi. (2021) Prognostic Impact of Ki-67 Change in Locally Advanced and Early Breast Cancer after Neoadjuvant Chemotherapy: A Single Institution Experience. Journal of Oncology 2021, pages 1-7.
Crossref
Crossref
Paula Cabrera-Galeana, Wendy Muñoz-Montaño, Fernando Lara-Medina, Alberto Alvarado-Miranda, Victor Pérez-Sánchez, Cynthia Villarreal-Garza, R. Marisol Quintero, Fany Porras-Reyes, Enrique Bargallo-Rocha, Ignacio Del Carmen, Alejandro Mohar & Oscar Arrieta. (2018) Ki67 Changes Identify Worse Outcomes in Residual Breast Cancer Tumors After Neoadjuvant Chemotherapy. The Oncologist 23:6, pages 670-678.
Crossref
Crossref
Leigh Neumayer & Rebecca K. Viscusi. 2018. The Breast. The Breast
531
552.e6
.
Lun Li, Dongdong Han, Xiaowei Wang, Quan Wang, Jinhui Tian, Jia Yao, Liqin Yuan, Ke Qian, Qiongyan Zou, Wenjun Yi, Enxiang Zhou & Kehu Yang. (2017) Prognostic values of Ki-67 in neoadjuvant setting for breast cancer: a systematic review and meta-analysis. Future Oncology 13:11, pages 1021-1034.
Crossref
Crossref
Edneia Tani, Nelson Fuentes-Martinez & Lambert Skoog. (2017) A Review of the Use of Fine-Needle Aspiration Biopsy of Mammary Tumors for Diagnosis and Research. Acta Cytologica 61:4-5, pages 305-315.
Crossref
Crossref
Yu Gui, Shuman Xu, Xi Yang, Lu Gu, Ze Zhang, Xiangdong Luo & Li Chen. (2016) A meta-analysis of biomarkers for the prognosis of triple-negative breast cancer patients. Biomarkers in Medicine 10:7, pages 771-790.
Crossref
Crossref
Jean Bao, Nicholas Borja, Madhu Rao, James Huth, A. Marilyn Leitch, Aeisha Rivers, Rachel Wooldridge & Roshni Rao. (2015) Impact of weight change during neoadjuvant chemotherapy on pathologic response in triple‐negative breast cancer. Cancer Medicine 4:4, pages 500-506.
Crossref
Crossref
Ou Huang, Min Jiang, Xiao-song Chen, Jia-yi Wu, Wei-guo Chen, Ya-fei Li & Kun-wei Shen. (2014) Prognostic Factors of Survival in Pathologic Incomplete Response Patients with Locally Advanced Breast Cancer After Neoadjuvant Chemotherapy. Cell Biochemistry and Biophysics 71:2, pages 1181-1190.
Crossref
Crossref
Nobuaki Matsubara, Hirofumi Mukai, Mariko Masumoto, Masaoki Sasaki, Yoichi Naito, Satoshi Fujii & Noriaki Wada. (2014) Survival outcome and reduction rate of Ki-67 between pre- and post-neoadjuvant chemotherapy in breast cancer patients with non-pCR. Breast Cancer Research and Treatment 147:1, pages 95-102.
Crossref
Crossref
Nobuaki Matsubara, Hirofumi Mukai, Satoshi Fujii & Noriaki Wada. (2012) Different prognostic significance of Ki-67 change between pre- and post-neoadjuvant chemotherapy in various subtypes of breast cancer. Breast Cancer Research and Treatment 137:1, pages 203-212.
Crossref
Crossref
T. Yamaguchi & H. Mukai. (2012) Ki-67 Index Guided Selection of Preoperative Chemotherapy for HER2-positive Breast Cancer: A Randomized Phase II Trial. Japanese Journal of Clinical Oncology 42:12, pages 1211-1214.
Crossref
Crossref
A. Sheri & M. Dowsett. (2012) Developments in Ki67 and other biomarkers for treatment decision making in breast cancer. Annals of Oncology 23, pages x219-x227.
Crossref
Crossref
Roshni RaoVeronica CruzYan PengAmy Harker-MurrayBarbara B. HaleyHong ZhaoXian-Jin XieDavid Euhus. (2012) Bootcamp during Neoadjuvant Chemotherapy for Breast Cancer: A Randomized Pilot Trial. Breast Cancer: Basic and Clinical Research 6, pages BCBCR.S9221.
Crossref
Crossref
L. Skoog & E. Tani. (2011) Immunocytochemistry: an indispensable technique in routine cytology. Cytopathology 22:4, pages 215-229.
Crossref
Crossref
Bhumsuk Keam, Seock-Ah Im, Kyung-Hun Lee, Sae-Won Han, Do-Youn Oh, Jee Hyun Kim, Se-Hoon Lee, Wonshik Han, Dong-Wan Kim, Tae-You Kim, In Ae Park, Dong-Young Noh, Dae Seog Heo & Yung-Jue Bang. (2011) Ki-67 can be used for further classification of triple negative breast cancer into two subtypes with different response and prognosis. Breast Cancer Research 13:2.
Crossref
Crossref
Mallika Tewari, Satyajit Pradhan, Usha Singh, Taj Bali Singh & Hari Shankar Shukla. (2010) Assessment of Predictive Markers of Response to Neoadjuvant Chemotherapy in Breast Cancer. Asian Journal of Surgery 33:4, pages 157-167.
Crossref
Crossref
Ou Huang, CanMing Chen, JiaYi Wu, ShuJie Chen, XiaoSong Chen, GuangYu Liu, Zhen Hu, JingSong Lu, Jiong Wu, ZhiMin Shao, ZhenZhou Shen & KunWei Shen. (2009) Retrospective analysis of 119 Chinese noninflammatory locally advanced breast cancer cases treated with intravenous combination of vinorelbine and epirubicin as a neoadjuvant chemotherapy: a median follow-up of 63.4 months. BMC Cancer 9:1.
Crossref
Crossref
Robin L. Jones, Janine Salter, Roger A’Hern, Ash Nerurkar, Marina Parton, Jorge S. Reis-Filho, Ian E. Smith & Mitchell Dowsett. (2008) The prognostic significance of Ki67 before and after neoadjuvant chemotherapy in breast cancer. Breast Cancer Research and Treatment 116:1, pages 53-68.
Crossref
Crossref
Mallika Tewari, Arvind Krishnamurthy & Hari S. Shukla. (2008) Predictive markers of response to neoadjuvant chemotherapy in breast cancer. Surgical Oncology 17:4, pages 301-311.
Crossref
Crossref
Ander Urruticoechea, Helena Aguilar, Xavier Solé, Gabriel Capellà, Lesley-Ann Martin, Mitch Dowsett & Josep Ramon Germà-Lluch. (2007) Pre-clinical validation of early molecular markers of sensitivity to aromatase inhibitors in a mouse model of post-menopausal hormone-sensitive breast cancer. Breast Cancer Research and Treatment 109:3, pages 463-470.
Crossref
Crossref
Amy L. Adams, Isam Eltoum, Helen Krontiras, Wenquan Wang & David C. Chhieng. (2008) The Effect of Neoadjuvant Chemotherapy on Histologic Grade, Hormone Receptor Status, and Her2/neu Status in Breast Carcinoma. The Breast Journal 14:2, pages 141-146.
Crossref
Crossref
Neal S. Goldstein, David Decker, Dawn Severson, Scott Schell, Frank Vicini, Jeffrey Margolis & Nayana S. Dekhne. (2007) Molecular classification system identifies invasive breast carcinoma patients who are most likely and those who are least likely to achieve a complete pathologic response after neoadjuvant chemotherapy. Cancer 110:8, pages 1687-1696.
Crossref
Crossref
Max S. Mano, Daniela D. Rosa, Evandro De Azambuja, Gustavo F.V. Ismael & Virginie Durbecq. (2007) The 17q12-q21 amplicon: Her2 and topoisomerase-IIα and their importance to the biology of solid tumours. Cancer Treatment Reviews 33:1, pages 64-77.
Crossref
Crossref
S. Chuthapisith, J.M. Eremin, M. El-Sheemy & O. Eremin. (2006) Neoadjuvant chemotherapy in women with large and locally advanced breast cancer: Chemoresistance and prediction of response to drug therapy. The Surgeon 4:4, pages 211-219.
Crossref
Crossref
Russell Burcombe, George D Wilson, Mitch Dowsett, Ifty Khan, Paul I Richman, Frances Daley, Simone Detre & Andreas Makris. (2006) Evaluation of Ki-67 proliferation and apoptotic index before, during and after neoadjuvant chemotherapy for primary breast cancer. Breast Cancer Research 8:3.
Crossref
Crossref
Ksenija Kanjer, Zora Neskovic-Konstantinovic & Dragica Nikolic-Vukosavljevic. (2006) In vivo model for research of breast cancer biomarkers. Archive of oncology 14:3-4, pages 141-145.
Crossref
Crossref
Ander Urruticoechea, Ian E. Smith & Mitch Dowsett. (2005) Proliferation Marker Ki-67 in Early Breast Cancer. Journal of Clinical Oncology 23:28, pages 7212-7220.
Crossref
Crossref
Robert T Pu, Anne F Schott, David E Sturtz, Kent A Griffith & Celina G Kleer. (2005) Pathologic Features of Breast Cancer Associated With Complete Response to Neoadjuvant Chemotherapy. The American Journal of Surgical Pathology 29:3, pages 354-358.
Crossref
Crossref
Arnd H?nig, Lorenz Rieger, Marc Sutterlin, Johannes Dietl & Erich-Franz Solomayer. (2004) Preoperative Chemotherapy and Endocrine Therapy in Patients with Breast Cancer. Clinical Breast Cancer 5:3, pages 198-207.
Crossref
Crossref
M.S. Mano & A. Awada. (2004) Primary chemotherapy for breast cancer: the evidence and the future. Annals of Oncology 15:8, pages 1161-1171.
Crossref
Crossref
Anne Vincent-Salomon, Alexandra Rousseau, Michel Jouve, Philippe Beuzeboc, Brigitte Sigal-Zafrani, Paul Fr?neaux, Christophe Rosty, Claude Nos, Fran?ois Campana, Jerzy Klijanienko, Abir Al Ghuzlan & Xavier Sastre-Garau. (2004) Proliferation markers predictive of the pathological response and disease outcome of patients with breast carcinomas treated by anthracycline-based preoperative chemotherapy. European Journal of Cancer 40:10, pages 1502-1508.
Crossref
Crossref
Daisuke Shimizu, Takashi Ishikawa, Yasushi Ichikawa, Shinji Togo, Yoshihide Hayasizaki, Yasushi Okazaki & Hiroshi Shimada. (2004) Current progress in the prediction of chemosensitivity for breast cancer. Breast Cancer 11:1, pages 42-48.
Crossref
Crossref
R.L Hayward & J.M Dixon. (2003) Current limits of knowledge in adjuvant and neoadjuvant endocrine therapy of breast cancer: the need for more clinical research. Surgical Oncology 12:4, pages 289-304.
Crossref
Crossref
T. Aas, S. Geisler, G.E. Eide, D.F. Haugen, J.E. Varhaug, A.M. Bassøe, T. Thorsen, H. Berntsen, A.-L. Børresen-Dale, L.A. Akslen & P.E. Lønning. (2003) Predictive value of tumour cell proliferation in locally advanced breast cancer treated with neoadjuvant chemotherapy. European Journal of Cancer 39:4, pages 438-446.
Crossref
Crossref
I F Faneyte, J G Schrama, J L Peterse, P L Remijnse, S Rodenhuis & M J van de Vijver. (2003) Breast cancer response to neoadjuvant chemotherapy: predictive markers and relation with outcome. British Journal of Cancer 88:3, pages 406-412.
Crossref
Crossref
Catherine Shannon & Ian Smith. (2003) Is there still a role for neoadjuvant therapy in breast cancer?. Critical Reviews in Oncology/Hematology 45:1, pages 77-90.
Crossref
Crossref
S. Iqbal, T.J. Anderson, L.P. Marson, R.J. Prescott, J.M. Dixon & W.R. Miller. (2002) MIB-1 Assessments in breast cancers. The Breast 11:3, pages 252-256.
Crossref
Crossref
Reiki Nishimura, Kazuharu Nagao, Haruhiko Miyayama, Masakazu Matsuda, Ken-ichirou Baba, Yukio Matsuoka, Hiroya Yamashita & Makoto Fukuda. (2002) An evaluation of predictive factors involved in clinical or pathological response to primary chemotherapy in advanced breast cancer. Breast Cancer 9:2, pages 145-152.
Crossref
Crossref
Tadashi Ikeda, Hiromitsu Jinno, Akira Matsui, Shigeru Masamura & Masaki Kitajima. (2002) The role of neoadjuvant chemotherapy for breast cancer treatment. Breast Cancer 9:1, pages 8-14.
Crossref
Crossref
Ian E Smith & Lara Lipton. (2001) Preoperative/neoadjuvant medical therapy for early breast cancer. The Lancet Oncology 2:9, pages 561-570.
Crossref
Crossref
K. Mokbel, A.C. A. Leris, J. Chang, T.J. Powles, D.C. Allred, S.E. Ashley, G.M. Clark & M. Dowsett. (2000) SPECIAL DEPARTMENTS. Journal of Clinical Oncology 18:7, pages 1601-1602.
Crossref
Crossref